191 related articles for article (PubMed ID: 38632276)
1. Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone.
Türkmen D; Bowden J; Masoli JAH; Delgado J; Kuo CL; Melzer D; Pilling LC
Pharmacogenomics J; 2024 Apr; 24(3):12. PubMed ID: 38632276
[TBL] [Abstract][Full Text] [Related]
2. Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients.
Türkmen D; Masoli JAH; Delgado J; Kuo CL; Bowden J; Melzer D; Pilling LC
Br J Clin Pharmacol; 2023 Feb; 89(2):853-864. PubMed ID: 36134646
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).
Niu Y; Gong Y; Langaee TY; Davis HM; Elewa H; Beitelshees AL; Moss JI; Cooper-Dehoff RM; Pepine CJ; Johnson JA
Circ Cardiovasc Genet; 2010 Dec; 3(6):548-55. PubMed ID: 21156931
[TBL] [Abstract][Full Text] [Related]
6. Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies.
McDonough CW; Warren HR; Jack JR; Motsinger-Reif AA; Armstrong ND; Bis JC; House JS; Singh S; El Rouby NM; Gong Y; Mychaleckyj JC; Rotroff DM; Benavente OR; Caulfield MJ; Doria A; Pepine CJ; Psaty BM; Glorioso V; Glorioso N; Hiltunen TP; Kontula KK; Arnett DK; Buse JB; Irvin MR; Johnson JA; Munroe PB; Wagner MJ; Cooper-DeHoff RM
Clin Pharmacol Ther; 2021 Sep; 110(3):723-732. PubMed ID: 34231218
[TBL] [Abstract][Full Text] [Related]
7. RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment.
Lynch AI; Irvin MR; Boerwinkle E; Davis BR; Vaughan LK; Ford CE; Aissani B; Eckfeldt JH; Arnett DK; Shrestha S
Pharmacogenomics J; 2013 Aug; 13(4):330-4. PubMed ID: 22664477
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up.
Jeong HS; Lim HS; Park HJ; Lee WS; Choi JO; Lee HS; Jo SH; Hong SJ
Sci Rep; 2021 Jan; 11(1):1783. PubMed ID: 33469103
[TBL] [Abstract][Full Text] [Related]
9. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Chen YJ; Li LJ; Tang WL; Song JY; Qiu R; Li Q; Xue H; Wright JM
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008170. PubMed ID: 30480768
[TBL] [Abstract][Full Text] [Related]
10. Measured Blood Pressure, Genetically Predicted Blood Pressure, and Cardiovascular Disease Risk in the UK Biobank.
Cho SMJ; Koyama S; Ruan Y; Lannery K; Wong M; Ajufo E; Lee H; Khera AV; Honigberg MC; Natarajan P
JAMA Cardiol; 2022 Nov; 7(11):1129-1137. PubMed ID: 36169945
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Zhang X; Lynch AI; Davis BR; Ford CE; Boerwinkle E; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
PLoS One; 2012; 7(3):e34217. PubMed ID: 22470539
[TBL] [Abstract][Full Text] [Related]
12. Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.
Matsumoto S; Kondo T; Yang M; Campbell RT; Docherty KF; de Boer RA; Desai AS; Lam CSP; Packer M; Pitt B; Rouleau JL; Vaduganathan M; Zannad F; Zile MR; Solomon SD; Jhund PS; McMurray JJV
Eur J Heart Fail; 2023 Dec; 25(12):2202-2214. PubMed ID: 37771260
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
JAMA; 2008 Jan; 299(3):296-307. PubMed ID: 18212314
[TBL] [Abstract][Full Text] [Related]
14. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy.
Lee SA; Choi HM; Park HJ; Ko SK; Lee HY
Korean J Intern Med; 2014 May; 29(3):315-24. PubMed ID: 24851066
[TBL] [Abstract][Full Text] [Related]
15. Application of calcium channel blockers in the treatment of cardiovascular diseases.
Herman ZS
Pol J Pharmacol; 1999; 51(2):201-6. PubMed ID: 10425650
[TBL] [Abstract][Full Text] [Related]
16. A genetic variant in the catechol-O-methyl transferase (COMT) gene is related to age-dependent differences in the therapeutic effect of calcium-channel blockers.
Xu J; Boström AE; Saeed M; Dubey RK; Waeber G; Vollenweider P; Marques-Vidal P; Mwinyi J; Schiöth HB
Medicine (Baltimore); 2017 Jul; 96(30):e7029. PubMed ID: 28746172
[TBL] [Abstract][Full Text] [Related]
17. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
18. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
Moore KH; Clemmer JS
Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
[TBL] [Abstract][Full Text] [Related]
19. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
[TBL] [Abstract][Full Text] [Related]
20. Calcium channel blockers suppress daily variations of blood pressure in hypertensive patients with end-stage renal diseases.
Takenaka T; Sueyoshi K; Arai J; Watanabe Y; Takane H; Ohno Y; Suzuki H
Clin Exp Hypertens; 2014; 36(2):78-82. PubMed ID: 24625333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
